ME01259B - Nova terapeutska upotreba adrenergičkog alfuzosina - Google Patents

Nova terapeutska upotreba adrenergičkog alfuzosina

Info

Publication number
ME01259B
ME01259B MEP-2011-204A MEP20411A ME01259B ME 01259 B ME01259 B ME 01259B ME P20411 A MEP20411 A ME P20411A ME 01259 B ME01259 B ME 01259B
Authority
ME
Montenegro
Prior art keywords
alfuzosine
adrenergic
therapeutic uses
novel therapeutic
novel
Prior art date
Application number
MEP-2011-204A
Other languages
English (en)
Inventor
Pierangelo Geppetti
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ME01259B publication Critical patent/ME01259B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Alfuzosin ili njegove farmaceutski prihvatljive soli za upotrebu u liječenju i/iliprevjencijuupale mokraćne bešikePatent sadrži još 9 patentnih zahtjeva.
MEP-2011-204A 2007-09-26 2008-09-24 Nova terapeutska upotreba adrenergičkog alfuzosina ME01259B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97532407P 2007-09-26 2007-09-26
EP07291148A EP2042179A1 (en) 2007-09-26 2007-09-26 Novel therapeutic uses of adrenergic alpha-1 receptor antagonists
EP08833688A EP2203170B1 (en) 2007-09-26 2008-09-24 NOVEL THERAPEUTIC USES OF ADRENERGIC ALFUZOsINE
PCT/IB2008/003126 WO2009040671A1 (en) 2007-09-26 2008-09-24 Novel therapeutic uses of adrenergic alpha-1 receptor antagonists

Publications (1)

Publication Number Publication Date
ME01259B true ME01259B (me) 2013-06-20

Family

ID=38754714

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2011-204A ME01259B (me) 2007-09-26 2008-09-24 Nova terapeutska upotreba adrenergičkog alfuzosina

Country Status (15)

Country Link
US (1) US8492396B2 (me)
EP (2) EP2042179A1 (me)
JP (1) JP5478495B2 (me)
AR (1) AR068825A1 (me)
AT (1) ATE524185T1 (me)
CY (1) CY1112203T1 (me)
DK (1) DK2203170T3 (me)
ES (1) ES2373354T3 (me)
HR (1) HRP20110919T1 (me)
ME (1) ME01259B (me)
PL (1) PL2203170T3 (me)
PT (1) PT2203170E (me)
RS (1) RS52069B (me)
SI (1) SI2203170T1 (me)
WO (1) WO2009040671A1 (me)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201907400YA (en) * 2018-07-18 2020-02-27 Univ Wenzhou Medical Method for treating myopia and application in preparation of medicament

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
CA2295572C (en) * 1997-07-10 2010-07-06 Therakos, Inc. Treatment of inflammatory disorders of the bowel and urinary bladder
EP2039357A2 (en) * 2001-01-26 2009-03-25 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
WO2002062389A1 (fr) * 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
WO2002069906A2 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
US20050261344A1 (en) * 2002-08-14 2005-11-24 Jones Charles R Treatment of lower urinary tract symptoms associated with overactive bladder in men and women
CA2530312A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
WO2007047282A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms

Also Published As

Publication number Publication date
WO2009040671A4 (en) 2009-05-28
RS52069B (en) 2012-06-30
EP2203170B1 (en) 2011-09-14
HRP20110919T1 (hr) 2012-01-31
WO2009040671A1 (en) 2009-04-02
DK2203170T3 (da) 2012-01-16
EP2203170A1 (en) 2010-07-07
ES2373354T3 (es) 2012-02-02
ATE524185T1 (de) 2011-09-15
US8492396B2 (en) 2013-07-23
PT2203170E (pt) 2011-12-27
PL2203170T3 (pl) 2012-02-29
SI2203170T1 (sl) 2012-01-31
US20110009436A1 (en) 2011-01-13
EP2042179A1 (en) 2009-04-01
JP2010540511A (ja) 2010-12-24
JP5478495B2 (ja) 2014-04-23
CY1112203T1 (el) 2015-12-09
AR068825A1 (es) 2009-12-09

Similar Documents

Publication Publication Date Title
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
ECSP10010361A (es) Derivados de piridazinona
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
NO20093542L (no) Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
RS54185B1 (en) USE OF 24-ORDER
ATE502935T1 (de) C-met-proteinkinasehemmer
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
TW200716577A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
TW200833342A (en) 2-substituted pyrimidines I in therapy
NO20075662L (no) Roflumilast for behandlingen av pulmonal hypertensjon